Solution Biologics Sdn. Bhd.
Solution Group Berhad (“SGB”) announces plan to venture into the business of vaccines and biologics with the Memorandum of Understanding (“MOU”) with CanSino Biologics Inc. (“CanSinoBIO”, SHSE:688185, HKEX:06185) for the supply of vaccines especially the Covid-19 vaccine into Malaysia.
SGB has incorporated a new wholly-owned subsidiary, Solution Biologics Sdn. Bhd., to undertake the supply of vaccines and biologics. For the initial phase of the business, Solution Biologics Sdn. Bhd will operates a fill and finish facility dedicated to vaccines and biologics. The facility will be housed in the current manufacturing building at Technology Park Malaysia and expected to be operational by first quarter of 2021.
Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market.
Since biologics are quite large in comparison to chemical-based drugs and made up of proteins, they require extra care to maintain their size, shape, form, and stability. These factors correlate to the intended effect and efficiency of the biologic drug.
In the area of vaccines, there’s no doubt that immunization saves millions of lives every year from vaccine-preventable diseases and one of the success stories in global health. More than 20 life-threatening diseases can now be prevented by immunization, and new vaccines for major killers like meningitis, cervical cancer, cholera and influenza are now being introduced in many countries. Today, vaccination is increasingly protecting health among people of all ages.
SGB has signed a MOU with CanSinoBIO to help to market the potential Covid-19 vaccine co-developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB).
With the incorporation of Solution Biologics Sdn. Bhd., as a biopharmaceutical company, SGB will enter into the life sciences business and will work to deliver vaccines and biologics that can help millions in Malaysia, the ASEAN region and around the world.
We are committed to developing newer and more effective vaccines and biologics through research and development programme with our partners. Our plan for the future will include paediatric and adult vaccines that are part of the National Immunisation Schedule of Malaysia and the Extended Programme of Immunisation (EPI) of various countries in the region.
Incorporated in 2009, CanSinoBIO (SHSE:688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector). Additional information can be found online at www.cansinotech.com.
Board of Directors
Lim Yong Hew, a Malaysian aged 60, is our founder and Group Managing Director of the Solution Group Berhad. He graduated with a Bachelor of Engineering in Electrical Engineering (Hons) majoring in Control and Instrumentation from Salford University in 1982. He started his career with George Kent Malaysia as a Project Engineer. He then joined Foxboro Malaysia in 1985 as a Sales Engineer. He left the company to establish Solution Engineering Sdn Bhd (SESB) in 1988 where he took on the position of Managing Director. With his extensive business experience, Mr Lim has been the main driving force of the Group. His responsibilities cover various aspects of the Group’s overall business development, direction and corporate strategy.
Dato' Dr. Mohd Nazlee Kamal, PhD.,a Malaysian aged 57, is our Director and Chief Executive Officer. He holds a PhD. in Chemical Engineering from University of Queensland, Brisbane, Australia, a M.App.Sc in Biotechnology from University of New South Wales. Australia, and a Bachelor of Science in Chemical Engineering from Oregon State University, Oregon, USA.
Dato' Dr. Mohd Nazlee has over 30 years of diverse industry background in strategy, biotechnology and life sciences which including 15 years of executive management experience. He possesses strong expertise in both technical and business aspects in these areas. With the recognition of his wide industrial leadership, he played a pivotal role in the formulation of Malaysia’s National Biotechnology Policy in 2005. Using his exceptional expertise and network, he provided consultation to various organisations and small medium enterprises within the industry.
Dato' Dr. Mohd Nazlee served as a CEO of Bioeconomy Corporation (previously known as BiotechCorp) from 2011-2016. He played a leadership role in the rebranding and repositioning of the company to facilitate the nation’s trajectory into the World Bio-economy arena. He was also invited to serve on the Global Bio-economy Council in Berlin from 2015-2017.
Dato' Dr. Mohd Nazlee has a wealth of experience encompassing marketing and technical portfolio with multinational companies such as Amersham Biosciences, Sartorius and B. Braun Biotech. In addition, he invented the “External Spinfilter” now marketed by Sartorius BBI Systems (Patent No. PI9701436MY-131798-A).
He has assumed leadership roles and also served on the boards of MAGIC, FRIM, NIBM, Bioeconomy Corporation (previously known as Biotech Corporation).
Charles Lim Meng Yit, a Malaysian aged 66, is our Director. He graduated from University of Science Malaysia as a Pharmacist with degree in B. Pharm.
Charles Lim is the founder of CLIENTS International Hong Kong healthcare biotechnology consulting company, he served as a CEO of the company from 2007 -2009, he assisted clients in business & distributor management and sourcing of fundings, facilitate technology transfer & acquisition in Asia Pacific. Consulting and business management for Atoll GmbH, BIA Separations and Bio-Works Co. Ltd. Cooperate with Emergene GmbH (CEO Dr Joachim Walter) to provide business plan and consultations for turnkey MAB production. Appointed expert advisor to Thailand Center of Excellence for Life Sciences (TCELS).
Charles Lim served as a General Manager of BIA Separations Co. Ltd. China & Asia Pacific and Vice President Business Development of BIA Separations Austria from 2010 – 2014 . He is incharged of sales, marketing and business development in China and Asia. Championed CIM Monolith Technology for downstream processing of large biomolecules in Asia Pacific.
Charles has diverse industry background in life science product sales, marketing & business development in asia pacific, bioseparations and protein purification from lab to production scale, bioprocess development and cGMP Bioproduction and process monitoring, downstream processing & development of biologics and vaccines, Turnkey plasma fractionation projects and biosafety, GMP facility design – conceptual and management pharmaceutical manufacturing technologies
Charles Lim is a Speaker and presenter at more that 40 local and International Seminars and Conferences on Vaccines, Biologics and Plasma Products in the Asia Pacific region and chaired/moderated several sessions. Lectured in protein and vaccine purification courses at institutes and universities.
Currently, Charles Lim is a Director of Lisure Science (Suzhou) Co., Ltd, he is also a consultant of International Business to Lisure Science (Suzhou) Co., Ltd, Suzhou Nanomicro Technology Company and Charles River Laboratory.